Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chondroitin Sulfate for Mild to Moderate Crohn's Disease
NCT01245088Phase 2Withdrawn
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jan 2011
- Primary completion
- Mar 2012
- Modality
- Biomacromolecule, Polysaccharide, GAG (Glycosaminoglycan)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chondroitin sulfate in Crohn's disease, sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Biologic effect on inflammation assessed through serum and tissue cytokine analysis at 8 weeks. Planned start Jan 2011; status: withdrawn.
02
Drugs
chondroitin sulfate
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01245088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245088.